for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE.N

Latest Trade

39.82USD

Change

-0.89(-2.19%)

Volume

6,547,300

Today's Range

39.64

 - 

40.93

52 Week Range

33.97

 - 

44.55

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
40.71
Open
40.93
Volume
6,547,300
3M AVG Volume
401.37
Today's High
40.93
Today's Low
39.64
52 Week High
44.55
52 Week Low
33.97
Shares Out (MIL)
5,534.12
Market Cap (MIL)
220,368.80
Forward P/E
--
Dividend (Yield %)
3.82

Next Event

Q4 2019 Pfizer Inc Earnings Release

Latest Developments

More

Pfizer's Greenstone And Digital Men's Health Clinic Roman Collaborate

Biogen To Acquire Novel Clinical Stage Asset With Application In Alzheimer’S Disease And Parkinson’S Disease From Pfizer Inc.

Axsome Therapeutics Enters Into Exclusive License Agreement With Pfizer For Pfizer’s Reboxetine Clinical And Nonclinical Data And For New Phase 3 Esreboxetine Product Candidate

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Contact Info

235 E 42ND ST

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Albert Bourla

Chairman of the Board, Chief Executive Officer

Frank A. D'Amelio

Chief Financial Officer, Executive Vice President - Business Operations

Mikael G. Dolsten

President - Worldwide Research and Development

Michael Goettler

Group President - Pfizer Upjohn

Angela Hwang

Group President - Pfizer Essential Health

Key Stats

2.50 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

52.8K

2017

52.5K

2018

53.6K

2019(E)

51.7K
EPS (USD)

2016

2.400

2017

2.650

2018

3.000

2019(E)

2.968
Price To Earnings (TTM)
14.65
Price To Sales (TTM)
4.15
Price To Book (MRQ)
3.39
Price To Cash Flow (TTM)
10.15
Total Debt To Equity (MRQ)
80.89
LT Debt To Equity (MRQ)
55.36
Return on Investment (TTM)
11.37
Return on Equity (TTM)
9.13

Latest News

Latest News

Biogen to buy early-stage potential Alzheimer's, Parkinson's treatment from Pfizer

Biogen Inc said on Monday it has agreed to buy an early-stage experimental treatment from Pfizer Inc that it aims to test in patients with Alzheimer's and Parkinson's disease.

Fed Circuit rules against Pfizer in sedative patent dispute

A federal appeals court Thursday upheld a patent ruling that allowed healthcare company Fresenius Kabi to launch a generic version of Pfizer Inc's sedative Precedex Premix.

China approves home-grown vaccines, offering alternative to global drugmakers' products

(This Dec 31 story corrects to show GSK did not participate in the development of Cecolin, in sixth and seventh paragraph.)

Exclusive: Drugmakers from Pfizer to GSK to hike U.S. prices on over 200 drugs

Drugmakers including Pfizer Inc <PFE.N>, GlaxoSmithKline PLC <GSK.L> and Sanofi SA <SASY.PA> are planning to hike U.S. list prices on more than 200 drugs in the United States on Wednesday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.

CORRECTED-China approves sales of first domestically developed 13-valent pneumonia vaccine

China has approved a pneumonia vaccine developed by domestic drugmaker Walvax Biotechnology , its National Medical Products Administration said in a notice on Tuesday, offering an alternative to Pfizer's market-dominating Prevnar 13.

FDA approves first generic of Bristol-Myers, Pfizer's blood thinner Eliquis

The U.S. Food and Drug Administration said on Monday it has approved the first generic version of Bristol-Myers Squibb Co and Pfizer Inc's blood thinner Eliquis.

UPDATE 1-FDA approves expanded label for Pfizer, Astellas' prostate cancer therapy Xtandi

The U.S. Food and Drug Administration has approved Pfizer Inc and Astellas Pharma Inc's Xtandi to treat patients with a type of prostate cancer, the companies said on Monday.

FDA approves expanded label for Pfizer, Astellas' prostate cancer Xtandi

The U.S. Food and Drug Administration has approved Pfizer Inc and Astellas Pharma Inc's Xtandi to treat patients with a type of prostate cancer, the companies said on Monday.

Fed Circuit upholds Amgen's $70 million patent win against Pfizer

A federal appeals court on Monday upheld a jury verdict that Pfizer Inc's Hospira unit should pay $70 million for infringing on a Amgen Inc patent covering its anemia drug Epogen.

Fed Circuit upholds Amgen's $70 million patent win against Pfizer

A federal appeals court on Monday upheld a jury verdict that Pfizer Inc's Hospira unit should pay $70 million for infringing on a Amgen Inc patent covering its anemia drug Epogen.

Pfizer's rare disease drug gets EMA's positive recommendation

Pfizer Inc said on Friday the European Medicines Agency granted the company a positive recommendation for approval of its treatment for a rare disorder that occurs in patients with cardiomyopathy.

Pfizer's rare disease treatment wins EMA's positive recommendation

Pfizer Inc said on Friday the European Medicines Agency granted the company a positive recommendation for approval of its treatment for a rare disorder that occurs in patients with cardiomyopathy.

Pfizer, Novartis lead $2 billion spending spree on gene therapy production

Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines.

FOCUS-Pfizer, Novartis lead pharma spending spree on gene therapy production

Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines.

U.S. top court won't consider Pfizer challenge to California Lipitor cases

The U.S. Supreme Court on Monday declined to consider whether Pfizer Inc could seek the dismissal of lawsuits in California's state courts by more than 3,600 out-of-state women who claim they developed diabetes after using its anti-cholesterol drug Lipitor.

Judge upholds Endo patents on Adrenalin in loss for Pfizer generic unit

A judge on Thursday dealt a major setback to Pfizer Inc's Hospira in its bid to launch a generic version of Endo International plc's emergency allergy treatment Adrenalin.

European agency highlights blood clot risks from Pfizer's arthritis drug

Pfizer Inc's rheumatoid arthritis drug Xeljanz could increase the risk of blood clots in the lungs and in deep veins, the European Medicines Agency (EMA) said on Thursday.

Pfizer raises 2019 forecast as sales of cancer drug, heart medicine surge

Pfizer Inc <PFE.N> reported a higher-than-expected third-quarter profit on Tuesday on increased sales of cancer drug Ibrance and a strong launch of new heart medicine Vyndaqel, prompting the largest U.S. drugmaker to lift its earnings forecast for the year.

US STOCKS SNAPSHOT-Merck, Pfizer spur S&P 500 to record high; Alphabet weighs on Nasdaq

The S&P 500 hit a fresh record high on Tuesday, lifted by upbeat earnings from drugmakers Merck and Pfizer, while disappointing quarterly profit from Google-parent Alphabet kept the Nasdaq firmly in the negative territory.

US STOCKS SNAPSHOT-Wall Street dips at open after mixed earnings reports

Wall Street opened slightly lower on Tuesday as investors assessed a mixed batch of earnings reports, including from Google-parent Alphabet and big drugmakers Merck and Pfizer.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up